News &amp; Updates

Administrating pegfilgrastim 72 h after chemotherapy, compared with 24- and 48-h administration, results in reduced pegfilgrastim-induced bone pain (PIBP) and does not appear to increase the rates of neutropenia or febrile neutropenia (FN), reports a study.

Pegfilgrastim administered 72 h postchemo lessens bone pain

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

The first-in-class KRAS G12D–targeted protein degrader setidegrasib has demonstrated antitumour activity in patients with previously treated advanced non–small-cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma harbouring the KRAS G12D mutation, according to a phase I study.

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

Post-exposure prophylaxis-in-pocket (PIP) appears as effective as pre-exposure prophylaxis (PrEP) in improving quality of life (QoL) of individuals at low risk for HIV but may be a less costly option, according to a matched-control study presented at CROI 2026.

Post-exposure PIP comparable to PrEP for low-risk HIV, but more affordable

17 Apr 2026 by

Post-exposure PIP comparable to PrEP for low-risk HIV, but more affordable

17 Apr 2026

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

17 Apr 2026 by

Treatment with tirzepatide, a dual GLP-1* and GIP** agonist, significantly improves cardiovascular and renal outcomes in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial presented at ACC.26.

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

Stopping beta-blockers after a year of regular use does not appear to increase the risk of adverse clinical outcomes in myocardial infarction (MI) survivors without evidence of left ventricular systolic dysfunction or heart failure (HF), as shown in the SMART-DECISION trial.

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

MetS risk higher in children with primary hypertension

Children with hypertension, particularly those with primary hypertension, are vulnerable to developing metabolic syndrome (MetS), reveals a study.

MetS risk higher in children with primary hypertension

Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS

Silymarin therapy combined with lifestyle interventions can reduce and normalize liver enzyme levels in patients with nonalcoholic fatty liver disease (NAFLD) and associated metabolic syndrome (MetS), a recent study has shown.

Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS

16 Apr 2026

ICLAD predicts poor vascular outcomes after ischaemic stroke

The presence of intracranial large artery disease (ICLAD) is associated with poor composite vascular outcomes, myocardial infarction (MI), and vascular death, but not recurrence, in patients with acute ischaemic stroke, suggests a Singapore study.

ICLAD predicts poor vascular outcomes after ischaemic stroke

16 Apr 2026

Novel lithotripsy device fares well in PINNACLE-I trial

The PINNACLE-I trial shows the feasibility, safety, and efficacy of LithiX, a novel Hertz contact intravascular lithotripsy (HC-IVL) device, for the treatment of calcified coronary artery lesions.

Novel lithotripsy device fares well in PINNACLE-I trial